Center4research.org

NCHR backs FDA's proposed guidance to collect standardized race/ethnicity data in clinical trials, which is crucial for addressing safety and efficacy disparities. We also urge a new category, mandatory implementation, and improved diversity to ensure accurate representation and meaningful efficacy and safety data

NCHR supports CPSC's slip resistance testing proposal for flooring but urges more comprehensive safety standards that also evaluate exposure to dangerous chemicals and heavy metals, such as those in rubber flooring.

May 1, 2024: We strongly support H.R. 6468 which would expedite the removal of water beads from the market to prevent severe injuries and fatalities due to these products.

April 29, 2024: We strongly support today’s FDA's decision to regulate lab-developed tests. Unfortunately, FDA’s final rules has compromised on the critical issue of grandfathering thousands of tests on the already on the market.

April 29, 2024: FDA issues the final rule for lab-developed tests (LDTs) and we explain that the rule has a giant deadly loophole allowing thousands of diagnostic tests and genetic tests for cancer and other deadly diseases to be sold without evidence they are accurate.

EPA released its 2024 report on artificial turf, which says it contains dangerous chemicals but that the exposures are "generally safe.' NCHR's Dr. Diana Zuckerman asks what does that mean? If it is generally safe that means it isn't safe for everyone, but EPA doesn't explain how many will be harmed and doesn't explain what is known and not known. It's not credible.

April 16th, 2024: NCHR supports CMS’ proposed rule and policies to increase oversight of Medicare accrediting organizations by addressing conflicts of interest; establishing standards, processes, and definitions for state surveys and unannounced surveys; and revising the validation survey program. We provide four key recommendations to bolster CMS' proposal.

April 15, 2024 By Robert Langreth, Fiona Rutherford and Tanaz Meghjani One ALS drug made $400 million in sales for its maker. It doesn’t work. A cancer treatment brought in $500 million. That one turned out to have no effect on survival. A blood cancer medication made nearly $850 million before being withdrawn for two […]

April 10, 2024 Today I will talk about Chemicals and Heavy Metals in Artificial Turf, Playgrounds, and Neighborhood Lawns: Policies vs. Scientific  Evidence. I’m Dr. Diana Zuckerman and I’m president of the National Center for Health Research. Our nonprofit research center and think tank is staffed by scientists, medical professionals, and public health experts. We […]

Bloomberg news describes numerous cancer drugs and other treatments that FDA approved but were found to not work after companies made billions of dollars. Diana Zuckerman and Gregg Gonsalves explain that FDA approval used to take too long but the pendulum has swung too far so that expensive drugs that don't work and may be unsafe are costing patients and our healthcare system more than it can afford.